Food and Drug Administration

Pre-Market Evaluation of Abuse-Deterrent Properties of Opioid Drug Products Public Meeting

October 31, 2016 – Day 1: Evaluating the Abuse Deterrence of Generic Opioid Drug Products

Open Public Hearing

1. 2:15 pm	Michelle Harford, U.S. Pain Foundation
2. 2:25 pm	Alexander Kraus, Grunenthal USA, Inc.
3. 2:35 PM	Susan Oh, Academy of Managed Care Pharmacy
4. 2:45 PM	Ajit Roy, Lannett Company, Inc.
5. 2:55 PM	Jack Henningfield, Pinney Associates
6. 3:05 PM	Penny Levin, MS, Teva Pharmaceuticals
7. 3:15 PM	Simon Budman, Inflexxion